URGENT ACQUISITION OF OSIMERTINIB 80MG

This tender is for the urgent acquisition of Osimertinib 80mg. Osimertinib is a targeted therapy medication used primarily for the treatment of certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations (EGFR mutations). The 'urgent' nature of this procurement indicates a critical and immediate need for this medication, likely to commence or continue treatment for patients. The objective is to secure a rapid supply of this high-value pharmaceutical. Bidders are expected to confirm their ability to provide authentic Osimertinib 80mg that meets all regulatory and quality standards, and crucially, to ensure immediate or very short-term delivery. The tender documents will specify the exact quantities required, delivery timelines, and any necessary documentation or certifications. This procurement is vital for ensuring timely access to life-saving or life-extending cancer treatment for patients requiring this specific therapy.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 66,511.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.